Researchers in the Netherlands have provided evidence that a single dose of Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine is sufficient to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among people who have already been infected with the virus.
Menno de Jong and colleagues showed that among previously infected individuals, one dose of Pfizer-BioNTech’s BNT162b2 vaccine-induced neutralizing antibody titers exceeded those observed among infection-naïve individuals who had received two doses.
